Pharmaceutical

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

The takeover, which includes the candidate felzartamab, for immune-mediated diseases, diversifies Biogen’s scope.

Jul 4, 2024 - 04:00
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
The takeover, which includes the candidate felzartamab, for immune-mediated diseases, diversifies Biogen’s scope.
Read the original article

Tags:

Previous Article

Beacon secures $170m to advance ophthalmic gene therapies

Next Article

Emergent scores US medical countermeasure contracts worth over $250m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sales of antibiotics for food-producing animals dropped by more than half in Europe over the past decade

STAT+: Sales of antibiotics for food-producing animals ...

Nov 27, 2023

CDC advisory panel recommends seniors ‘may’ get RSV vaccine

CDC advisory panel recommends seniors ‘may’ get RSV vac...

Jun 22, 2023

STAT+: Pharmalittle: Bluebird claims big insurer will cover its sickle cell therapy; House Republicans threaten to subpoena FDA commish

STAT+: Pharmalittle: Bluebird claims big insurer will c...

Dec 15, 2023